source
- Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concernsNovartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
- Industry groups push for clearer FDA guidance on ANDA and 505(b)(2) filings amid rising patent thicketsIndustry trade groups representing brand‑name and generic manufacturers have asked the FDA to clarify its recent guidance on when a company should file an abbreviated new drug application (ANDA) ve…